CD38 and neoplasm: ISB 1442 antibody is distinguished due to three features: (i) it uses two distinct Fab arms to target a tumor associated antigen (biparatopic approach), allowing for improved CDC and improved binding to tumor cells when an antigen is downregulated; (ii) it blocks the CD47 ‘don’t eat me’ signal to counteract tumor escape from phagocytosis, leveraging selective avidity-induced binding to CD38+ tumor cells, thereby avoiding off-tumor targeting; and (iii) it is equipped with the Fc mutations enhancing effector mechanisms (CDC, ADCC and ADCP).